Brand Medications with Generic Alternatives Anticipated tobe Approved in February
January 21, 2022FDA Approves Fintepla Use in Broader Patient Population
March 28, 2022From: IPD Analytics:
RX Brief: Drug Management
Savings Opportunities with Upcoming Specialty and Traditional Generics
January, 2023 - The 2022 U.S. Generic and Biosimilar Medicines Savings Report, published by the Association for Accessible Medicines, found that the U.S. healthcare system saved $373 billion in 2021 (up from $338 billion in 2020) by using generic drugs and biosimilars. A key service of IPD Analytics is tracking upcoming losses of exclusivity (LOEs) and potential generic launches, which allows payers to implement proactive changes to drive utilization toward agents losing exclusivity or to develop clinical programs to enhance generic uptake. This report highlights cost-saving opportunities relating to key potential generic launches in 2023, noting drugs with significant 2021 U.S. sales and drugs that may be managed under the pharmacy benefit. Also included are details surrounding the generic outlook from patent and regulatory perspectives, important considerations for payers from a clinical perspective, and considerations for hospitals/health-systems (where relevant).